Treatment with Delayed-release Dimethyl Fumarate is Associated with Fewer Relapses versus Glatiramer Acetate in Patients with Relapsing Remitting Multiple Sclerosis: Real-world Comparative Effectiveness Analyses from the EFFECT Study

Mapping Intimacies ◽

10.26226/morressier.59a3edabd462b8028d89517d ◽

2017 ◽

Author(s):

Andrew Chan

Keyword(s):

Multiple Sclerosis ◽

Glatiramer Acetate ◽

Real World ◽

Comparative Effectiveness ◽

Dimethyl Fumarate ◽

Effect Study ◽

Delayed Release ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Delayed-release Dimethyl Fumarate Demonstrated No Difference in Clinical Outcomes versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Real-world EFFECT Study

10.26226/morressier.59a3e8b6d462b8028d8951f5 ◽

2017 ◽

Cited By ~ 1

Author(s):

Jacob Sloane

Keyword(s):

Multiple Sclerosis ◽

Clinical Outcomes ◽

Real World ◽

Dimethyl Fumarate ◽

Effect Study ◽

The Real ◽

Delayed Release ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Comparative Effectiveness Using A Matching-Adjusted Indirect Comparison Between Delayed-Release Dimethyl Fumarate and Fingolimod for The Treatment of Relapsing-Remitting Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2015.09.2902 ◽

2015 ◽

Vol 18 (7) ◽

pp. A750 ◽

Cited By ~ 3

Author(s):

RJ Fox ◽

G Cutter ◽

A Chan ◽

J Xiao ◽

M Okwuokenye ◽

...

Keyword(s):

Multiple Sclerosis ◽

Comparative Effectiveness ◽

Indirect Comparison ◽

Dimethyl Fumarate ◽

Delayed Release ◽

Relapsing Remitting ◽

Adjusted Indirect Comparison ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis

Neurology and Therapy ◽

10.1007/s40120-019-00174-3 ◽

2019 ◽

Vol 9 (1) ◽

pp. 85-92

Author(s):

Michelle Allan ◽

Lindsay Grant

Keyword(s):

Multiple Sclerosis ◽

Retrospective Analysis ◽

Real World ◽

Dimethyl Fumarate ◽

Delayed Release ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Effectiveness Of Delayed-Release Dimethyl Fumarate Compared To Glatiramer Acetate And Fingolimod For The Treatment Of Relapsing-Remitting Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2014.03.356 ◽

2014 ◽

Vol 17 (3) ◽

pp. A60-A61 ◽

Cited By ~ 2

Author(s):

J.A. Mauskopf ◽

M. Fay ◽

R. Iyer ◽

T. Livingston

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Dimethyl Fumarate ◽

Delayed Release ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis - findings from a real-world setting in Russian Federation

10.26226/morressier.5b719e475aff74008ae4cbeb ◽

2018 ◽

Author(s):

Maria Davydovskaya

Keyword(s):

Multiple Sclerosis ◽

Russian Federation ◽

Real World ◽

Dimethyl Fumarate ◽

Delayed Release ◽

Real World Setting ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Efficacy of Delayed-release Dimethyl Fumarate in Newly Diagnosed Patients With Relapsing-Remitting Multiple Sclerosis: Eight-Year Follow-up of an Integrated Analysis of DEFINE, CONFIRM, and ENDORSE

10.26226/morressier.59a3eda8d462b8028d895222 ◽

2017 ◽

Cited By ~ 1

Author(s):

Ralf Gold

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Integrated Analysis ◽

Newly Diagnosed ◽

Delayed Release ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Real World Comparative Effectiveness data of Natalizumab vs Fingolimod for the treatment of Relapsing-Remitting Multiple Sclerosis: Results from a Systematic Literature Review

10.26226/morressier.59a3edabd462b8028d8951ff ◽

2017 ◽

Author(s):

Carlos Acosta

Keyword(s):

Multiple Sclerosis ◽

Literature Review ◽

Systematic Literature Review ◽

Real World ◽

Comparative Effectiveness ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis ◽

Effectiveness Data

Download Full-text

PND19 CLINICAL AND ECONOMIC IMPACT OF INITIATING DIMETHYL FUMARATE VERSUS GLATIRAMER ACETATE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN EUROPE

Value in Health ◽

10.1016/j.jval.2019.04.1292 ◽

2019 ◽

Vol 22 ◽

pp. S273

Author(s):

M. Rock ◽

T. Dort ◽

S. Snyder ◽

M. Gitlin

Keyword(s):

Multiple Sclerosis ◽

Economic Impact ◽

Glatiramer Acetate ◽

Dimethyl Fumarate ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Corrigendum to “Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: 9 Years’ Follow-up of DEFINE, CONFIRM, and ENDORSE”

Therapeutic Advances in Neurological Disorders ◽

10.1177/1756286420968357 ◽

2020 ◽

Vol 13 ◽

pp. 175628642096835

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Safety And Efficacy ◽

Delayed Release ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Incidence and mitigation of gastrointestinal events in patients with relapsing–remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE)

Therapeutic Advances in Neurological Disorders ◽

10.1177/1756286418768775 ◽

2018 ◽

Vol 11 ◽

pp. 175628641876877 ◽

Cited By ~ 9

Author(s):

Ralf Gold ◽

Eugen Schlegel ◽

Birte Elias-Hamp ◽

Christian Albert ◽

Stephan Schmidt ◽

...

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Delayed Release ◽

Gastrointestinal Events ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis ◽

Phase Iv

Download Full-text